Sunitinib in thymic carcinoma: Enigmas still unresolved

The Lancet Oncology

Volumn 16, Issue 2, 2015, Pages 124-125

  Marx, Alexander ^a   Weis, Cleo Aron ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PROGNOSIS; CANCER SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GENE TARGETING; HUMAN; MOLECULARLY TARGETED THERAPY; NOTE; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; THYMOMA; THYMUS CANCER; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; MALE; NEOPLASM RECURRENCE, LOCAL; NEUROENDOCRINE TUMORS; THYMUS NEOPLASMS;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INDOLES; MALE; NEOPLASM RECURRENCE, LOCAL; NEUROENDOCRINE TUMORS; PYRROLES; THYMOMA; THYMUS NEOPLASMS;

EID: 84921873062     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)70010-0     Document Type: Note

References (9)

1. Travis WD, Brambilla E, Muller-Hermelink H, Harris C Pathology and genetics of tumours of the lung, pleura, thymus and heart 2004, IARC Press, Lyon.
2. Petrini I, Meltzer PS, Kim IK, et al. A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat Genet 2014, 46:844-849.
3. Okuma Y, Saito M, Hosomi Y, Sakuyama T, Okamura T Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy. J Cancer Res Clin Oncol 2014, published online Aug 22. http://dx.doi.org/10.1007/s00432-014-1800-6.
4. Litvak AM, Woo K, Hayes S, et al. Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of Masaoka staging. J Thorac Oncol 2014, 9:1810-1815.
5. Thomas A, Rajan A, Berman A, et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol 2015, published online Jan 13. http://dx.doi.org/10.1016/S1470-2045(14)71181-7.
6. Strobel P, Hartmann M, Jakob A, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 2004, 350:2625-2626.
7. Strobel P, Bargou R, Wolff A, et al. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer 2010, 103:196-200.
8. Kao J, Ko EC, Eisenstein S, Sikora AG, Fu S, Chen SH Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol 2011, 77:12-19.
9. Rini BI, Stein M, Shannon P, et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 2011, 117:758-767.